TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1512659

Group type: EXPERIMENTAL
Intervention: FPL acuity testing
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: FPL acuity
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: VEP acuity
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Acuity difference score (FPL minus VEP)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Rating scores of visual behaviors
Number of subjects: 42
Study: 6386512

Group type: EXPERIMENTAL
Intervention: Sustained-release terbutaline, 7.5 mg 2 times/day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Ordinary salbutamol tablets, 4 mg 3 times/day
Number of subjects: 25
Study: 31180829

Group type: EXPERIMENTAL
Intervention: nBETTER therapy (EEG-based MI-BCI with visual feedback)
Number of subjects: 13

Group type: COMPARATOR
Intervention: BCI with haptic knob (BCI-HK)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Standard arm therapy (SAT)
Number of subjects: 13
Study: 29335328

Group type: EXPERIMENTAL
Intervention: 10 000 steps per day prescription for 10 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (normal activity habits)
Number of subjects: 46
Study: 27430612

Group type: EXPERIMENTAL
Intervention: ATX-101
Number of subjects: 258

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study: 25154607

Group type: EXPERIMENTAL
Intervention: Udenafil (100 mg daily for three months)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 23713743

Group type: EXPERIMENTAL
Intervention: Remifentanil 3 ng/mL
Number of subjects: 10

Group type: COMPARATOR
Intervention: Methylnaltrexone 0.15 mg/kg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 10
Study: 19924497

Group type: EXPERIMENTAL
Intervention: Balloon kyphoplasty (BKP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-surgical management
Number of subjects: 0
Study: 18768020

Group type: EXPERIMENTAL
Intervention: Tapered filament toothbrush (TFTB)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control toothbrush (ADA)
Number of subjects: 32
Study: 16819358

Group type: EXPERIMENTAL
Intervention: Modified Tissue Tonometer (MTT)
Number of subjects: 24
Study: 16583964

Group type: EXPERIMENTAL
Intervention: General anesthesia + epidural anesthesia combined group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (only general anesthesia)
Number of subjects: 50
Study: 10815350

Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM) interventions
Number of subjects: 258

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 258
Study: 9193380

Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (50 mg/day)
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: beta-carotene (20 mg/day)
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: alpha-tocopherol and beta-carotene (50 mg/day and 20 mg/day respectively)
Number of subjects: 1862

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1862
Study: 8194434

Group type: COMPARATOR
Intervention: daily‐aspirin‐treated group (aspirin, 300mg, once everyday)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: intermittent‐aspirin‐treated group (aspirin, 300mg, once every three days)
Number of subjects: 42

Group type: COMPARATOR
Intervention: non‐aspirin‐treated group
Number of subjects: 42

Group type: COMPARATOR
Intervention: normal subjects group
Number of subjects: 42
Study: 3517243

Group type: EXPERIMENTAL
Intervention: High-dose cisplatin (100 mg/m2)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Low-dose cisplatin (20 mg/m2) and chlorambucil
Number of subjects: 91
Study: 29708829

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (1000 mg i.m. every 10 weeks)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 27682295

Group type: EXPERIMENTAL
Intervention: InterTAN nail (ITN)
Number of subjects: 78

Group type: COMPARATOR
Intervention: third generation gamma nail (GN)
Number of subjects: 78
Study: 24530176

Group type: EXPERIMENTAL
Intervention: Intensive treatment (target systolic blood pressure <140 mm Hg within 1 h using locally available intravenous drugs)
Number of subjects: 2839

Group type: COMPARATOR
Intervention: Guideline-recommended treatment (target systolic blood pressure <180 mm Hg within 6 h of onset of ICH)
Number of subjects: 2839

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 2839

Group type: COMPARATOR
Intervention: Guideline-recommended treatment
Number of subjects: 2839
Study: 22931483

Group type: EXPERIMENTAL
Intervention: Non-commercial music for 45 minutes at nocturnal sleep time
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 28
Study: 20591807

Group type: EXPERIMENTAL
Intervention: Cranial electrical stimulation (CES)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study: 18412023

Group type: EXPERIMENTAL
Intervention: Ampicillin 500 mg capsules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference product (not specified)
Number of subjects: 0
Study: 16618841

Group type: EXPERIMENTAL
Intervention: Angiotensin II (8.8+/‐1.4 ng/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sodium nitroprusside (2.0+/‐0.3 microg/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Norepinephrine (52+/‐12 ng/kg)
Number of subjects: 6
Study: 12590029

Group type: EXPERIMENTAL
Intervention: Valdecoxib 40 mg daily plus morphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valdecoxib 80 mg daily plus morphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus morphine
Number of subjects: 0
Study: 10954937

Group type: EXPERIMENTAL
Intervention: Dermatology-trained practice nurse intervention
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 109
Study: 8614421

Group type: EXPERIMENTAL
Intervention: Screening for cervical chlamydial infection
Number of subjects: 2607

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2607
Study: 1283088

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (two cycles of cisplatin, bleomycin, vindesine, mitomycin C)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (three cycles of cisplatin, 5-fluorouracil continuous infusion, and vindesine)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Chemotherapy (both regimens)
Number of subjects: 208
Study: 3884019

Group type: EXPERIMENTAL
Intervention: 2% dimethyl sulfoxide (DMSO)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 70% dimethyl sulfoxide (DMSO)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 0.85% normal saline
Number of subjects: 84
Study: 30815973

Group type: EXPERIMENTAL
Intervention: Mobile phone application (MPA) only (Group C)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Both MPA and self-monitoring of blood glucose (SMBG) (Group D)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose (SMBG) only (Group B)
Number of subjects: 185

Group type: COMPARATOR
Intervention: No MPA and no SMBG (Group A)
Number of subjects: 185
Study: 28850712

Group type: EXPERIMENTAL
Intervention: Fluoride varnish applications every six months
Number of subjects: 275

Group type: COMPARATOR
Intervention: Placebo applications every six months
Number of subjects: 275
Study: 26730446

Group type: EXPERIMENTAL
Intervention: Extended release guanfacine hydrochloride (1-6 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 24691730

Group type: EXPERIMENTAL
Intervention: Levothyroxine for 14 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: No medication (control) for 14 days
Number of subjects: 12
Study: 22070196

Group type: EXPERIMENTAL
Intervention: PureVision high addition multifocal contact lenses (PM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Spectacles
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Contrast sensitivity
Number of subjects: 20
Study: 20522709

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy regimens consisting of cytosine arabinoside (Ara‐C), daunorubicin (D), and etoposide (E) with PSC‐833 (ADEP)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Induction chemotherapy regimens consisting of cytosine arabinoside (Ara‐C), daunorubicin (D), and etoposide (E) without PSC‐833 (ADE)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: ADEP (with PSC‐833)
Number of subjects: 302

Group type: COMPARATOR
Intervention: ADE (without PSC‐833)
Number of subjects: 302
Study: 17999333

Group type: EXPERIMENTAL
Intervention: Gum arabic (50 g day(‐1)) treatment with low-protein diet (LPD) (<40 g day(‐1)) in group A
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Gum arabic (50 g day(‐1)), iron (ferrous sulphate, 200 mg day(‐1)), and folic acid (5 mg day(‐1)) treatment in group B
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Gum arabic (50 g day(‐1)) treatment in normal volunteers (group D)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (group C): CRF patients under LPD and iron and folic acid treatment
Number of subjects: 36
Study: 19922878

Group type: EXPERIMENTAL
Intervention: DPSGC 25 mg
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 15178380

Group type: EXPERIMENTAL
Intervention: Auditory semantic and morpho-syntactic priming paradigm with German adjectives correctly or incorrectly inflected for gender and semantically associated or not associated with the target noun.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Auditory semantic and morpho-syntactic priming paradigm with German adjectives.
Number of subjects: 0
Study: 11718157

Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m2 every three weeks)
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 477

Group type: COMPARATOR
Intervention: Good palliative care
Number of subjects: 477

Group type: COMPARATOR
Intervention: Vinorelbine or ifosfamide
Number of subjects: 477
Study: 9863072

Group type: EXPERIMENTAL
Intervention: Selenium (Se) supplement (1 mg orally on the second day of hospitalization)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 75
Study: 7887118

Group type: EXPERIMENTAL
Intervention: Edrophonium (EDR) 0.5 mg kg‐1 + atropine (ATR) 0.007 mg kg‐1
Number of subjects: 64

Group type: COMPARATOR
Intervention: Neostigmine (NST) 0.04 mg kg‐1 + glycopyrrolate (GLY) 0.008 mg kg‐1
Number of subjects: 64
Study: 3394630

Group type: EXPERIMENTAL
Intervention: Self-reported psychological distress levels
Number of subjects: 125

Group type: COMPARATOR
Intervention: Known predictors of arrhythmias (including cardiac risk, age, beta-blocker agents)
Number of subjects: 125
Study: 31506292

Group type: EXPERIMENTAL
Intervention: Selonsertib (18 mg)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Selonsertib (2 mg)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Selonsertib (6 mg)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333
Study: 28834453

Group type: EXPERIMENTAL
Intervention: Intravesical rAd-IFNα/Syn3 (1 × 10^11 vp/mL)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Intravesical rAd-IFNα/Syn3 (3 × 10^11 vp/mL)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Intravesical rAd-IFNα/Syn3
Number of subjects: 43
Study: 26802597

Group type: EXPERIMENTAL
Intervention: Adjunctive topiramate (TPM)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Olanzapine (OLZ)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low baseline thyrotropin profile (TSHAUC)
Number of subjects: 100
Study: 25529911

Group type: EXPERIMENTAL
Intervention: Regular nursing rounds every 1‐2 hours
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 100
Study: 22277179

Group type: EXPERIMENTAL
Intervention: Ultrafiltration (UF)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional diuretic (CD) therapy
Number of subjects: 36
Study: 19535222

Group type: EXPERIMENTAL
Intervention: Right ventricular apical (RVA) pacing
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intrinsic atrioventricular conduction
Number of subjects: 30
Study: 17456217

Group type: EXPERIMENTAL
Intervention: Topical fluticasone propionate (FP) 100 microg daily
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Topical fluticasone propionate (FP) 400 microg daily
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 16235834

Group type: EXPERIMENTAL
Intervention: Small dense LDL (sdLDL) prevalence rate analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Severity of Type 2 DM classified by HbA1c value
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prevalence rate of sdLDL in relation to complications (microangiopathy and macroangiopathy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation of sdLDL with serum TG level
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum level of TG-rich remnants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessment of sdLDL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conclusion on sdLDL levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation of sdLDL with severity and modalities for complications
Number of subjects: 0
Study: 12172896

Group type: EXPERIMENTAL
Intervention: Skin protection measures (SP), no specific dosage or duration mentioned
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Ultraviolet B (UVB) hardening, no specific dosage or duration mentioned
Number of subjects: 94

Group type: COMPARATOR
Intervention: No intervention (controls)
Number of subjects: 94
Study: 10213261

Group type: EXPERIMENTAL
Intervention: Albuterol delivered by metered dose inhaler (MDI) and spacer
Number of subjects: 8

Group type: COMPARATOR
Intervention: Albuterol delivered by low-flow nebulizer (NEB)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both MDI and NEB
Number of subjects: 8
Study: 7794851

Group type: EXPERIMENTAL
Intervention: 5 mg dydrogesterone
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: 10 mg dydrogesterone
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: 15 mg dydrogesterone
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: 20 mg dydrogesterone
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: All doses
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: At least 10 mg dydrogesterone
Number of subjects: 371
Study: 1977371

Group type: EXPERIMENTAL
Intervention: Prednisone (80 mg/d orally for 5 days)
Number of subjects: 12
Study: 365122

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30448166

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (sham procedure)
Number of subjects: 70
Study: 28244495

Group type: EXPERIMENTAL
Intervention: Tenapanor 50 mg b.i.d.
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Tenapanor 20 mg b.i.d.
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Tenapanor 5 mg b.i.d.
Number of subjects: 356

Group type: COMPARATOR
Intervention: Placebo b.i.d.
Number of subjects: 356
Study: 23914770

Group type: EXPERIMENTAL
Intervention: Shockwave lithotripsy (SWL)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Semirigid ureteroscopy (URS)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Shockwave lithotripsy (SWL) for stones <10 mm
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Semirigid ureteroscopy (URS) for stones <10 mm
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Shockwave lithotripsy (SWL) for stones 10 to 20 mm
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Semirigid ureteroscopy (URS) for stones 10 to 20 mm
Number of subjects: 180
Study: 22502601

Group type: EXPERIMENTAL
Intervention: 3% sodium hypochlorite (NaOCl)
Number of subjects: 65

Group type: COMPARATOR
Intervention: 1:5 dilution of Buckley's formocresol (FC)
Number of subjects: 65
Study: 21871113

Group type: EXPERIMENTAL
Intervention: Dietary plan with an energy deficit of 1200 kcal/day, strengthening exercises (15 min/hour), cognitive behavioral training (30 min/hour) during working hours 1 hour/week, leisure time aerobic fitness for 2 hour/week
Number of subjects: 98

Group type: COMPARATOR
Intervention: Monthly oral presentations
Number of subjects: 98
Study: 19720797

Group type: EXPERIMENTAL
Intervention: Ala carriers (Ala/Ala or Ala/Pro)
Number of subjects: 1119

Group type: EXPERIMENTAL
Intervention: Pro/Pro homozygotes
Number of subjects: 1119

Group type: COMPARATOR
Intervention: ACE inhibitor therapy in Pro/Pro homozygotes
Number of subjects: 1119

Group type: COMPARATOR
Intervention: Non-ACE inhibitor therapy in Pro/Pro homozygotes
Number of subjects: 1119
Study: 17904939

Group type: EXPERIMENTAL
Intervention: Ketogenic low-carbohydrate diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet (nonketogenic)
Number of subjects: 0
Study: 15472678

Group type: EXPERIMENTAL
Intervention: Transpancreatic septotomy sphincterotomy (n = 29)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Needle-knife sphincterotomy (n = 34)
Number of subjects: 63
Study: 11464180

Group type: EXPERIMENTAL
Intervention: Micronized isotretinoin (0.4 mg/kg per day, fasted)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard isotretinoin (1.0 mg/kg per day, fed, in two divided doses)
Number of subjects: 600
Study: 9541686

Group type: COMPARATOR
Intervention: hCRF 0.66 micrograms/kg/h
Number of subjects: 17

Group type: COMPARATOR
Intervention: hCRF 1 microgram/kg/h
Number of subjects: 17

Group type: COMPARATOR
Intervention: hCRF 2 micrograms/kg/h
Number of subjects: 17

Group type: COMPARATOR
Intervention: hCRF 4 micrograms/kg/h
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 7817832

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT)
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: Duration of ERT
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: Parity
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: Ethnic background
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 875
Study: 3048762

Group type: EXPERIMENTAL
Intervention: Alizapride plus dexamethasone (DXM)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo plus dexamethasone (DXM)
Number of subjects: 39
Study: 31391003

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) intervention
Number of subjects: 1035

Group type: EXPERIMENTAL
Intervention: Baseline testing
Number of subjects: 1035

Group type: EXPERIMENTAL
Intervention: HIVST intervention
Number of subjects: 1035

Group type: COMPARATOR
Intervention: No baseline testing
Number of subjects: 1035
Study: 29145868

Group type: EXPERIMENTAL
Intervention: Intervention group (Move for Well-being in School programme)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 148
Study: 26152132

Group type: EXPERIMENTAL
Intervention: Selexipag 1,600 μg b.i.d. (1 x 1,600 μg tablet)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Selexipag 1,600 μg b.i.d. (8 x 200 μg tablets)
Number of subjects: 80
Study: 23500307

Group type: EXPERIMENTAL
Intervention: Tissue Doppler echocardiography (TDE)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Brachial pulse pressure (bPP)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Aortic pulse wave velocity (PWV)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Aortic pulse pressure (aoPP)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Backward wave amplitude (Pb)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Measures of pulsatile function added to TDE
Number of subjects: 71

Group type: COMPARATOR
Intervention: TDE-based algorithm
Number of subjects: 71
Study: 21679712

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 119
Study: 19788023

Group type: EXPERIMENTAL
Intervention: Formoterol (12 microg)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Terbutaline (0.5 mg)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 79
Study: 16319215

Group type: EXPERIMENTAL
Intervention: Rotation about an off-vertical axis (OVAR) at various speeds and tilt angles
Number of subjects: 6
Study: 14985565

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir and ribavirin
Number of subjects: 41

Group type: COMPARATOR
Intervention: ribavirin only
Number of subjects: 41
Study: 11239724

Group type: EXPERIMENTAL
Intervention: Day drug abuse treatment
Number of subjects: 261

Group type: COMPARATOR
Intervention: Residential drug abuse treatment
Number of subjects: 261
Study: 9613543

Group type: EXPERIMENTAL
Intervention: Sympathetic nerve blocks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Permanent sympathetic block with neurolytic or thermocoagulation techniques
Number of subjects: 0
Study: 8291151

Group type: EXPERIMENTAL
Intervention: Intensive training course on interpretation of electrocardiography (8 hours)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 107
Study: 2498105

Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate 40 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Chronic isosorbide‐5‐mononitrate
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 31671400

Group type: EXPERIMENTAL
Intervention: Logistic regression model incorporating six biomarkers (BHB, DHA, 1‐MedA, PdG, NAM, Xan)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Double-blind study for PTC and BTN
Number of subjects: 124
Study: 27496852

Group type: EXPERIMENTAL
Intervention: Store-and-forward teledermatology intervention
Number of subjects: 103

Group type: COMPARATOR
Intervention: Conventional referral (standard letters)
Number of subjects: 103
Study: 26014444

Group type: EXPERIMENTAL
Intervention: Intravenous unfractionated heparin (UFH) bolus (100 U/kg)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Patients who failed to reach targeted ACT value of >300 seconds at T10
Number of subjects: 102
Study: 22560048

Group type: EXPERIMENTAL
Intervention: Bifrontal electrode placement (BFECT; n = 62)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Bitemporal electrode placement (BTECT; n = 60)
Number of subjects: 122
Study: 20957515

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Combination of Fluoxetine and CBT (COMB)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 260